Navigation Links
Sinovac Receives Healive(R) and Bilive(R) Purchase Orders from Provincial CDCs for Earthquake Disaster Areas

BEIJING, June 16 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced that the Shanxi Center for Disease Control and Prevention (CDC) ordered 257,100 doses of Healive(R), the inactivated hepatitis A vaccine manufactured by Sinovac. On the same day, the Gansu CDC ordered 47,000 doses of Bilive(R), a combined hepatitis A and hepatitis B vaccine manufactured by Sinovac. The vaccine purchased by the local CDCs will be utilized to inoculate children in the disaster zones following the May 12th earthquake to prevent the infectious disease. Concurrently, Sinovac donated an additional 8,000 doses of Healive(R) to affected areas in the Shanxi Province. Sinovac's clinical experts were dispatched to the inoculation area to assist the local CDCs with immunization.

Mr. Weidong Yin, Chairman, CEO and President of Sinovac, commented, "The delivery of additional vaccines to the earthquake area reflects our consistent commitment to contribute to improving human health across China. Sinovac's highly efficient manufacturing operations enable us to play a significant role in supplying vaccines for the prevention of infectious diseases during emergency situations. Our established post sales service programs allow for the timely distribution of vaccines to the local CDC doctors in earthquake disaster areas."

As previously announced, the Beijing municipal government purchased on June 11 80,000 doses of Bilive(R), the combined inactivated hepatitis A and B vaccine manufactured by Sinovac, and the vaccines were delivered to disaster area in Gansu Province. Sinovac donated on May 19 to the earthquake disaster area 50,000 doses of Healive(R), of which 10,000 doses were sent to the Gansu province. On May 22, the Ministry of Health purchased approximately RMB 20 million of Healive(R).

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, . To be added to our distribution list, please email:

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact:

Helen G. Yang

Sinovac Biotech Ltd.

Tel: +86-10-8289-0088 x871

Fax: +86-10-6296-6910



Stephanie Carrington / Janine McCargo

The Ruth Group

Tel: +1-646-536-7017/7033

Email: /

SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac Receives RMB 20 Million Purchase Order for Healive from Chinas Ministry of Health to Vaccinate Earthquake Victims
2. Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008
3. Sinovac Biotech Holds Annual General Meeting
4. Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
5. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
6. Sinovac Announces Adjournment of Annual General Meeting
7. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
8. Sinovac Closes $9.75 Million Private Placement
9. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
10. Sinovac Requests Extension for Annual Shareholders Meeting
11. Sinovac Announces Postponement of Annual General Meeting
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):